RE:RE:RE:Precise radiation oncology Hi Skys1.As to cost it depends on the mode of treatment. Of course no Trial is cheap but in terms of treatment looks like they`ll be going with low dose X-ray in both indications and if GBM - for example - is to consist of a jab in a vein followed by stereotactic trans-cranial X-ray just how expensive is that likely to be?
Cost appears the winning advantage throughout in that competitors such as Roswell/Lumeda cannot use Rutherrin (which is patented Theralase property) and must choose from more limited photosensitisers combined with either interstitial PDT or the Lumeda OSA and associated software.
if Rutherrin really can be activated exogenously by low dose X-ray (and that`s what the anns are saying) then this game-changing advantage in elegance simplicity and cost will leave it unassallable until Sherri`s osmium compounds (themselves under long license to Theralase) hit the Clinic.
Theralase looks to be in the box seat with PDT and photochemotherapy. Its`intellectual property will be the envy of many powerful Companies and institutions hence MHO that the recent debacle may be seen as a time-limited opportunity by corporate predators.